An executive order by Trump rolled back some efforts by the Biden administration to control Medicare costs but it didn't ...

At least three government lawyers working on defending a major Biden-era drug pricing law were laid off in mass cuts across ...

Speaker Mike Johnson (R-La.) indicated this week that his approach to repealing the Democrats’ climate, tax, infrastructure ...

Manufacturers are responsible for meeting all four parts of the definition of bona fide service fee before a fee can qualify as a bona fide ...

The bill would allow Medicare to begin negotiating with pharmaceutical companies over prices for small molecule medicines 13 ...

A federal court rejected Novartis Pharmaceuticals’, a unit of Novartis AG (NYSE:NVS) legal challenge to the Medicare Drug ...

The Trump administration, perhaps surprisingly, chose to defend the legality of the Inflation Reduction Act’s (IRA’s) drug ...

While many industry players and observers have high hopes for the EPIC Act, some say budgetary headwinds could make it ...

An interview with former White House communications strategist Andrew Bates, who explains how Democrats can capitalize on ...

Prior authorization reforms, increased biosimilar access and the future of the Medicare drug price negotiation program are ...

Merck is bracing for the years of sales growth from oncology superstar Keytruda to take a sharp turn in 2028—and for more ...

This year, people on Medicare Part D will not have to pay more than $2,000 in out-of-pocket drug expenditures — and that ...